Domnich A, Trombetta C, Fallani E, Salvatore M
PLoS One. 2025; 19(12):e0310677.
PMID: 39775353
PMC: 11684710.
DOI: 10.1371/journal.pone.0310677.
Imran M, Puig-Barbera J, Ortiz J, Lopez-Gonzalez L, Dean A, Bonafede M
Influenza Other Respir Viruses. 2024; 18(4):e13288.
PMID: 38644564
PMC: 11033326.
DOI: 10.1111/irv.13288.
Youhanna J, Tran V, Hyer R, Domnich A
Influenza Other Respir Viruses. 2024; 18(4):e13286.
PMID: 38594827
PMC: 11004266.
DOI: 10.1111/irv.13286.
Frey S, Versage E, Van Twuijver E, Hohenboken M
Hum Vaccin Immunother. 2023; 19(1):2193119.
PMID: 37057755
PMC: 10114991.
DOI: 10.1080/21645515.2023.2193119.
Panatto D, Domnich A, Chironna M, Loconsole D, Napoli C, Torsello A
Vaccines (Basel). 2023; 11(1).
PMID: 36679928
PMC: 9861626.
DOI: 10.3390/vaccines11010083.
Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019-2020 Influenza Season.
Imran M, Puig-Barbera J, Ortiz J, Fischer L, OBrien D, Bonafede M
Open Forum Infect Dis. 2022; 9(5):ofac167.
PMID: 35493131
PMC: 9045943.
DOI: 10.1093/ofid/ofac167.
Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications.
Boikos C, Imran M, Nguyen V, Ducruet T, Sylvester G, Mansi J
Vaccines (Basel). 2021; 9(8).
PMID: 34451987
PMC: 8402367.
DOI: 10.3390/vaccines9080862.
Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK.
Stuurman A, Ciampini S, Vannacci A, Bella A, Rizzo C, Munoz-Quiles C
PLoS One. 2021; 16(6):e0252836.
PMID: 34129638
PMC: 8205138.
DOI: 10.1371/journal.pone.0252836.
Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis.
Coleman B, Sanderson R, Haag M, McGovern I
Influenza Other Respir Viruses. 2021; 15(6):813-823.
PMID: 34081398
PMC: 8542957.
DOI: 10.1111/irv.12871.
Overcoming immune dysfunction in the elderly: trained immunity as a novel approach.
Bulut O, Kilic G, Dominguez-Andres J, Netea M
Int Immunol. 2020; 32(12):741-753.
PMID: 32766848
PMC: 7680842.
DOI: 10.1093/intimm/dxaa052.
Immunogenicity Measures of Influenza Vaccines: A Study of 1164 Registered Clinical Trials.
Domnich A, Manini I, Panatto D, Calabro G, Montomoli E
Vaccines (Basel). 2020; 8(2).
PMID: 32575440
PMC: 7350243.
DOI: 10.3390/vaccines8020325.
Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil.
Apetito Akamatsu M, Sakihara V, Carvalho B, de Paiva Abrantes A, Takano M, Adami E
PLoS One. 2020; 15(6):e0233632.
PMID: 32492039
PMC: 7269237.
DOI: 10.1371/journal.pone.0233632.
Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis.
Yang J, Zhang J, Han T, Liu C, Li X, Yan L
Medicine (Baltimore). 2020; 99(7):e19095.
PMID: 32049815
PMC: 7035094.
DOI: 10.1097/MD.0000000000019095.
Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).
Can Commun Dis Rep. 2019; 37(ACS-6):1-68.
PMID: 31701945
PMC: 6802457.
DOI: 10.14745/ccdr.v37i00a06.
Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59 -adjuvanted influenza vaccine in older adults: Results from three consecutive seasons.
Panatto D, Haag M, Lai P, Tomczyk S, Amicizia D, Lino M
Influenza Other Respir Viruses. 2019; 14(1):61-66.
PMID: 31617965
PMC: 6928029.
DOI: 10.1111/irv.12685.
Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis.
Ng T, Cowling B, Gao H, Thompson M
J Infect Dis. 2018; 219(10):1525-1535.
PMID: 30551178
PMC: 6775043.
DOI: 10.1093/infdis/jiy720.
AS03- and MF59-Adjuvanted Influenza Vaccines in Children.
Wilkins A, Kazmin D, Napolitani G, Clutterbuck E, Pulendran B, Siegrist C
Front Immunol. 2018; 8:1760.
PMID: 29326687
PMC: 5733358.
DOI: 10.3389/fimmu.2017.01760.
Aging of the immune system: Focus on inflammation and vaccination.
Pinti M, Appay V, Campisi J, Frasca D, Fulop T, Sauce D
Eur J Immunol. 2016; 46(10):2286-2301.
PMID: 27595500
PMC: 5156481.
DOI: 10.1002/eji.201546178.
Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.
Magini D, Giovani C, Mangiavacchi S, Maccari S, Cecchi R, Ulmer J
PLoS One. 2016; 11(8):e0161193.
PMID: 27525409
PMC: 4985159.
DOI: 10.1371/journal.pone.0161193.
Early Rise of Blood T Follicular Helper Cell Subsets and Baseline Immunity as Predictors of Persisting Late Functional Antibody Responses to Vaccination in Humans.
Spensieri F, Siena E, Borgogni E, Zedda L, Cantisani R, Chiappini N
PLoS One. 2016; 11(6):e0157066.
PMID: 27336786
PMC: 4918887.
DOI: 10.1371/journal.pone.0157066.